Publications by authors named "G M Atlas"
Challenges in Care Provision for Children and Adolescents With Differences of Sex Development.
Clin Endocrinol (Oxf)
January 2025
Objectives: The ideal model of care for individuals with Differences of Sex Development (DSD) continues to evolve, with multiple models proposed. This study aimed to explore current care models for individuals with DSD in Australia and New Zealand (NZ) and to identify clinician perceptions of gaps and barriers in current practice.
Methods: Cross-sectional anonymous online questionnaire, conducted via Research Electronic Data Capture (REDCap) software.
Genomic testing for differences of sex development: Practices and perceptions of clinicians.
Clin Endocrinol (Oxf)
December 2024
Objectives: To investigate the approach taken by clinicians involved in the diagnosis and management of individuals with Differences of Sex Development (DSD), particularly with regard to genomic testing, and identify perceived gaps/strengths/barriers in current practice.
Design And Methods: An anonymous online survey was developed, with questions exploring demographics, perceptions of genomic testing, availability of genetics services and opinions on the role and utility of genomic testing in DSD. All responses were anonymous.
Background: Normal hypothalamic-pituitary-ovarian (HPO) endocrine function is essential for female pubertal and psychosocial development and for ongoing adult physical, sexual, and psychosocial health. Girls with hypogonadism, any endocrine disorder causing abnormal uterine bleeding (AUB) or with contraception needs may require sex hormone treatment. Challenges include evolving needs of a young girl through the course of sexual maturation, potential health risks related to the use of sex hormones for pubertal induction, hormone replacement therapy (HRT), menstrual management, and/or contraception.
View Article and Find Full Text PDFArticle Synopsis
- A phase 2 trial investigated the effects of baricitinib, a JAK inhibitor, on β-cell function in patients with early-stage type 1 diabetes, comparing it to a placebo over 48 weeks.
- Results showed that the baricitinib group had a significantly higher mean C-peptide level, indicating better β-cell function, and required a lower daily insulin dose compared to the placebo group.
- While baricitinib improved certain measures of insulin production and glycemic control, the overall levels of glycated hemoglobin were similar between both groups, with no notable differences in adverse events reported.